Syantra closed Series A-1 round

Syantra, Inc. raised an additional $4.9 million Canadian Dollars in Series A-1 funding. This funding round was from a collective of individuals introduced by CG Wealth Management, with additional support from existing investors.

Syantra is a privately held precision biotechnology company pioneering a platform to change the way cancer is detected and treated. The company will use the funds to fast-track clinical validation and commercialization of the first test on its patent-pending platform for the early detection of breast cancer.